摘要：

Compounds of general formula (1) ##STR1## are described wherein . dbd. W-- is (1) ═C(Y)-- where Y is a halogen atom, or an alkyl, (2) . dbd. N--; L is a --XR, [where R is an optionally substituted alkyl, alkenyl, cycloalkyl or cyloalkenyl group], Z is (1) a group --C(R. sup. 3)(R.sup.4) C(R.sup.5)(R.sup.6)(R.sup.7) or --C(R.sup.4)═C(R. sup.5)(R. sup.6) where R.sup.3 is a hydrogen or a fluorine atom or an optionally substituted straight or branched alkyl group; R.sup.4 is a group selected from --X.sup.a L.sup.1 R.sup.12 [where X.sup.a is as defined above for X, L.sup.1 is a linker group and R.sup.12 is a hydrogen atom or a cycloaliphatic, bicyclic aryl group --Alk.sup.1 R.sup.12 [where Alk. sup. 1 is an optionally substituted straight or branched alkenyl or alkynyl chain or Z is (2) a group --C(R.sup.4)C(R.sup.5)(R.sup.6)(R.sup. 7) where R.sup.4 is a group ═CH.sub.2, or ═CH(L.sup.1).sub.n -- R. sup.12 ; and the salts, solvates, hydrates, prodrugs and N-oxides thereof. Compounds according to the invention are phosphodiesterase type IV inhibitors and are useful in the prophylaxis and treatment of disease such as asthma where an unwanted inflammatory response or muscular spasm is present.

展开